NCT01088685已完成不适用
Feasibility Study to Evaluate the Safety and Performance of a Hydrogel Blister Patch Prototype for the Treatment of Foot Blisters
Johnson & Johnson Consumer and Personal Products Worldwide1 个研究点 分布在 1 个国家目标入组 93 人开始时间: 2010年3月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 93
- 试验地点
- 1
- 主要终点
- Investigator Assessment
研究概览
简要总结
Study to evaluate the safety and performance of a new blister patch intended to treat blisters on the heel of the foot.
详细描述
The study will require participation for up to 14 days of participation or less if the blister heals sooner, will recruit 100 subjects with fluid filled blisters on the heel of the foot that are intact and not broken. Some subjects will be asked to have their blisters photographed. All subjects will be required to have their blister unroofed (top layer of skin removed by the physician using sterile instruments). All subjects will receive study product, either test product or a marketed product.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects, 18 years of age or older;
- •Individuals who are willing and able to provide informed consent
- •Female subjects of child bearing potential must have a negative urine pregnancy test prior to application of the study products;
- •Females of childbearing potential must be using a medically-acceptable method of birth control for at least one month prior to Visit 1 such as the ones listed below and agree to continue using this method during their participation in the study; Note that abstinence is not an approved method of birth control.
- •Postmenopausal or amenorrheic for one year
- •Surgically sterile (hysterectomy, tubal ligation, or oophorectomy)
- •Use of an effective method of birth control (e.g. prescription oral contraceptives, contraceptive implants or injections, intrauterine device, diaphragm, cervical cap or condoms with spermicide)
- •Individuals exhibit a blister on the heel that is determined by the investigator to be no more than 72 hours old and in stage 2
- •Subject is willing to have blister unroofed (top layer of blister removed) by the investigator
- •Subject is willing and able to follow the study directions, to participate in the study, and to return for all specified visits
排除标准
- •Pregnant, planning a pregnancy or actively nursing
- •Exhibits a foot blister on the heel that exceeds 1125mm2 or would otherwise not be covered by the hydrogel portion of the study product
- •Unstable or uncontrolled medical conditions that could require intensive treatment during the course of the study
- •Individuals with autoimmune disorders including, but not limited to, lupus erythematosus, rheumatoid arthritis, or HIV/AIDS
- •Currently participating in or, within the past 30 days have participated in another clinical study using an investigational drug or device
- •Employees of the site, or friends/relatives of employees that would have access to study information
- •Diabetic, type I or type II
- •Treatment for any type of cancer within the last 2 years or history of skin cancer
- •Damaged skin in or around test sites, which include sunburn, extremely deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, acne, and disfiguration of the test site
- •History of clinically determined allergic reaction or irritation to any of the test product ingredients
- •History of or known allergy to iodine
- •Currently taking or expected to take any of the following during the course of the study: amphetamines, benzodiazepines, cocaine, marijuana, methaqualone, methadone, opiates, propoxyphene, barbiturates, and phencyclidine
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
研究组 & 干预措施
Experimental Blister Patch
Experimental
Experimental Hydrogel Blister patch
干预措施: Experimental Blister Patch (Device)
Marketed Pflaster
Active Comparator
Scholls Blasen Pflaster
干预措施: Marketed Pflaster (Device)
结局指标
主要结局
Investigator Assessment
时间窗: at subject's last visit, within 14 days of start
Global assessment of the product by the investigator at the subject's last visit.
次要结局
- Time to Heal(Baseline to subject's last visit, within 14 days of start)
- Subject Assessment(at subject's last visit, within 14 days of start)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK SurgeryDry Eye SyndromeNCT00544713Allergan228
终止
不适用
Study To Assess Radiofrequency Diathermocontraction Device For Muscle Stimulation And The Treatment Of Abdominal FatAbdominal FatMuscle StimulationNCT05388617Cynosure, Inc.16
已完成
不适用
A Feasibility Study to Evaluate the Safety and Effectiveness of Implantation of Flowise Cerebral Flow Diverter (Flowise)Intracranial AneurysmNCT02609867Yonsei University10
进行中（未招募）
不适用
Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft SystemIliac Artery StenosisNCT04023370Bentley InnoMed GmbH182
已完成
不适用
Study to Evaluate Using a Cold Sore Patch to Treat Herpes LabialisHerpes LabialisNCT01208298Johnson & Johnson Consumer and Personal Products Worldwide45